When was Stemedica founded?

Stemedica was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Where is Stemedica located?

Stemedica is headquartered in San Diego, United States.

How many employees does Stemedica have?

As of Mar 01, 2026, the latest employee count at Stemedica is 10 - 49.

Is Stemedica a funded company?

Stemedica is a funded company, having raised a total of $32M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 2007.

When was the latest funding round of Stemedica?

Stemedica's latest funding was a $***** Series B round on Dec 31, 2009, with participation from 0 investor.

Where does Stemedica rank among its competitors?

Stemedica ranks 234th amongst 1975 active competitors, of which 463 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Stemedica?

Stemedica's top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Stemedica - 2026 Company Profile, Funding & Competitors

Stemedica is a series B company based in San Diego (United States), founded in 2005. It operates as a Biopharmaceutical company developing progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has raised $32M in funding. The company has 1975 active competitors, including 463 funded and 334 that have exited. Its top competitors include companies like Synthego, Antheia and Transcenta.

Company Details

Biopharmaceutical company developing progenitor cell and protein therapeutics for underserved medical conditions. They focus on advancing clinical trials for critical illnesses using their proprietary platform technology. This technology produces progenitor cell products meeting stringent quality standards in a cGMP licensed facility. They are pioneering allogeneic progenitor cell therapies, including ischemia-tolerant mesenchymal stem cells (itMSCs) for ischemic stroke and Alzheimer’s disease, and ischemia-tolerant neural progenitor cells (itNSCs) for spinal cord injury. Their research and development efforts extend to progenitor multi-cell therapy and progenitor cell and protein combination therapy, aiming to provide innovative solutions for unmet medical needs.

Website: www.stemedica.com/
Social

Key Metrics

Founded Year

2005

Location

San Diego, United States

Stage

Series B

Total Funding

$32M in 2 rounds

Latest Funding Round

Series B, Dec 31, 2009, $*****

Investors

The Gramercy Fund

Ranked

234^th among 1975 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Synthego & 2685 more

View Stemedica's full profile

Stemedica is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Stemedica Cell Technologies, Inc. CIN: 203096698 , United States, Active	Jan 06, 2005	-	50 (As on Dec 31, 2023)	-

Stemedica has raised a total funding of $32M over 2 rounds. Its first funding round was on Jul 2007. Stemedica has 1 institutional investor.

Here is the list of recent funding rounds of Stemedica:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 31, 2009	4408530	Series B	7431614	7066975	2675905	2746913
Jul 2007	8422406	Series A	7597414	3457334	7185335	8211782

Access funding benchmarks and valuations. Sign up today!

View details of Stemedica's funding rounds and investors

Stemedica's employee count trend

Stemedica has 10 - 49 employees as of Mar 26. Here is Stemedica's employee count trend over the years:

Uncover Stemedica's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Stemedica include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Stemedica, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	General Catalyst, Vivo Capital & 12 others	65/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Sino Biopharmaceutical, Orbimed & 18 others	65/100
7th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Humboldt Fund & 7 others	65/100
8th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Verition Fund Management ... & 14 others	64/100
9th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
10th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
234th	Stemedica 2005, San Diego (United States), Series B	Biopharmaceutical company developing progenitor cell and protein therapeutics for underserved medical conditions	$32M	The Gramercy Fund	42/100